Evaluation of golimumab for the treatment of patients with active rheumatoid arthritis

Expert Opinion on Drug Metabolism & Toxicology
Yoshiya TanakaDaniel Baker

Abstract

Golimumab is a human anti-TNF monoclonal antibody that was derived from human antibody-transgenic mice. Golimumab demonstrated meaningful clinical benefit and tolerable safety in patients with active rheumatoid arthritis (RA) who were methotrexate (MTX)-naïve, or who inadequately responded to MTX or who had previously been treated with a TNF inhibitor. This review summarizes published data on the clinical efficacy and safety for golimumab (including its pharmacodynamic and pharmacokinetic characteristics) from multiple global phase III and Japanese phase II/III clinical trials. In the long term extension of three Phase III studies with subcutaneous golimumab, the reported retention rate is high. Golimumab binds TNF with high affinity and can be delivered subcutaneously every 4 weeks. Like other IgG1 antibodies, FcγR functions suggests that antibody dependent cellular cytotoxicity is observed but the contribution of cell lysis to efficacy is unclear. Although anti-TNFα agents made it possible to achieve clinical remission in RA patients, there is still an unmet need to develop treatments that will enable them to discontinue all RA medication and maintain drug-free remission.

References

Aug 6, 1998·Annals of Hematology·J E GessnerR E Schmidt
Mar 22, 2001·The New England Journal of Medicine·E H Choy, G S Panayi
May 10, 2002·Immunologic Research·Victor Ghetie, E Sally Ward
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Jun 9, 2005·Seminars in Arthritis and Rheumatism·Marc C HochbergDavid E Yocum
Sep 10, 2005·Nature Biotechnology·Nils Lonberg
Feb 16, 2006·Drug Discovery Today·Mohammad A TabriziLorin K Roskos
Feb 4, 2009·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Zehra KaymakcalanEric H Sasso
Mar 3, 2010·Rheumatology·Takahiko HoriuchiTerufumi Shimoda
Feb 1, 2011·Seminars in Arthritis and Rheumatism·Roberto Perez-AlvarezManuel Ramos-Casals
Nov 29, 2011·Annals of the Rheumatic Diseases·Yoshiya TanakaUNKNOWN GO-FORTH Study Group
Dec 14, 2011·The New England Journal of Medicine·Iain B McInnes, Georg Schett
May 15, 2013·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Hideji FujiiYasushi Harada
Feb 20, 2014·Annals of the Rheumatic Diseases·Gerd-Rudiger BurmesterRoy M Fleischmann
May 15, 2015·Annals of the Rheumatic Diseases·Josef S SmolenDesirée van der Heijde
Nov 8, 2015·Arthritis & Rheumatology·Jasvinder A SinghTimothy McAlindon

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.